US equities
|
NVDA
$234.52
▲+1.59%
MU
$1,075.79
▼-1.97%
SPCX
$159.18
▲+7.50%
TSLA
$372.39
▲+5.16%
SNDK
$1,721.93
▼-3.68%
STX
$843.26
▼-10.82%
AMD
$632.16
▲+2.67%
INTC
$119.71
▼-0.24%
NVDA
$234.52
▲+1.59%
MU
$1,075.79
▼-1.97%
SPCX
$159.18
▲+7.50%
TSLA
$372.39
▲+5.16%
SNDK
$1,721.93
▼-3.68%
STX
$843.26
▼-10.82%
AMD
$632.16
▲+2.67%
INTC
$119.71
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Relief Therapeutics Hldg
(OP:
RLFTF
)
0.2655
UNCHANGED
Last Price
Updated: 2:52 PM EDT, Aug 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relief Therapeutics Hldg
< Previous
1
2
3
4
5
6
7
Next >
Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
November 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has signed a collaboration agreement (the "...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
November 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Launches Level 1 ADR Program in the United States
November 18, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 18, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), announced today that its Form F-6 registration statement has become effective,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
November 12, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 12, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100(TM) (Aviptadil)
November 11, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development
November 09, 2021
- Anthony M. Kim Appointed Senior Vice President and Head of U.S. Commercial Operations - Seasoned Biotech Executive Brings Vast U.S. Commercial Launch Experience to Relief - European and United...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
↗
November 05, 2021
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing...
Via
Benzinga
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
November 05, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 5, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Takes First Step to Create an ADR Program in the United States by Filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
November 03, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), announced today that it has taken the first steps to establish a Level 1 American...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
November 03, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment
↗
October 27, 2021
Relief Therapeutics Holding SA's (OTC: RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of...
Via
Benzinga
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
October 27, 2021
Results Confirm the Safety and Tolerability of Sentinox and Suggest It Could Be Effective in Reducing Time to Negativization in SARS-CoV-2 Infected Patients GENEVA, SWITZERLAND / ACCESSWIRE / October...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers
October 20, 2021
A Prospective Series on Wound Bed Preparation with Nexodyn(R) AOS and Standard of Care and a 32-Week Follow-Up Study Published in the Peer Reviewed Journal of Wound Care GENEVA, SWITZERLAND /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Why NRx Pharmaceuticals Stock Is Tumbling Today
↗
October 15, 2021
The drugmaker is being sued by Relief Therapeutics.
Via
The Motley Fool
Topics
Lawsuit
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
October 15, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
October 13, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / October 13, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)
October 06, 2021
Lawsuit alleges multiple breaches of Collaboration Agreement GENEVA, SWITZERLAND / ACCESSWIRE / October 7, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), today announced that...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review
↗
October 06, 2021
The FDA has accepted for review Acer Therapeutics Inc (NASDAQ: ACER) and its partner, Relief Therapeutics Holding SA's (OTC: RLFTF) marketing...
Via
Benzinga
Relief Reports that U.S. Collaboration Partner Announced Second Favorable Safety Report for ZYESAMI(TM) (RLF-100TM/aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Life-Threatening COVID-19
September 30, 2021
GEVENVA, SWITZERLAND / ACCESSWIRE / September 30, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
↗
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers
September 30, 2021
As an Active Cleanser, Nexodyn(R) AOS Shows Superior Wound Healing Performance Compared to Standard of Care GENEVA, SWITZERLAND / ACCESSWIRE / September 30, 2021 / RELIEF THERAPEUTICS Holding SA...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)
September 28, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / September 28, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports Half-Year 2021 Results and Provides Corporate Update
September 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / September 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief's Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic(TM) Technology
September 21, 2021
- Data In Healthy Volunteers Suggests That APR's Controlled Release Amino Acid Mix, PKU GOLIKE(R) , May Be Key To Reducing Catabolic Events In Patients With Phenylketonuria ("PKU"), Improving...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)
September 13, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / September 13, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE(R) KRUNCH in Germany and Italy
September 09, 2021
APR Expands PKU GOLIKE(R) Product Line with More Convenient, Chewable Tablet Option GENEVA, SWITZERLAND / ACCESSWIRE / September 9, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / September 8, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021
September 07, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / September 7, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), commented today on statements made by NRx Pharmaceuticals, Inc....
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis
September 02, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
August 31, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / August 31, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
< Previous
1
2
3
4
5
6
7
Next >
